Study: NCT05480800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose
Description: 3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose
Description: 3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid conjugate vaccine (TCV) low dose
Description: 3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose
Description: 3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose
Description: 3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose
Description: 3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose
Description: 3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid conjugate vaccine (TCV) full dose
Description: 3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid conjugate vaccine (TCV) full dose
Description: 3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's Meningococcal A, C, Y and W-135 conjugate vaccine
Description: 1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control_Stage 2 Group in Stage 2 (Africa).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Description: 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control_Stage 2 Group in Stage 2 (Africa).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
Description: 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control_Stage 2 Group in Stage 2 (Africa).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).